Tresiba Regulatory Status: US, EU, Canada, and UK Approvals Explained

What Is the Regulatory Status of Tresiba in the United States?

The FDA approved insulin degludec (Tresiba) on September 25, 2015, under NDA 203313 for adults with type 1 and type 2 diabetes mellitus. A pediatric extension followed, expanding the label to children aged 1 year and older. The approval came after an initial Complete Response Letter in 2013 requesting cardiovascular outcomes data, which Novo Nordisk addressed through the DEVOTE trial. Tresiba is classified as a prescription-only drug under federal law and is not available over the counter.

The 2013 Complete Response Letter

The FDA's initial refusal to approve insulin degludec in February 2013 centered on pre-specified cardiovascular risk thresholds. The agency required that the upper bound of the 95% confidence interval for major adverse cardiovascular events (MACE) remain below 1.8 in a dedicated outcomes trial before approval. This was an unusually high bar at the time and delayed US availability by approximately 32 months relative to the EU.

How DEVOTE Unlocked US Approval

DEVOTE enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk and compared degludec U-100 against glargine U-100 over a median of 2.0 years. The trial was published in the New England Journal of Medicine in 2017 [1]. The hazard ratio for first MACE was 0.91 (95% CI 0.78 to 1.06), satisfying both non-inferiority (upper bound <1.3) and the original FDA threshold. Severe hypoglycemia was significantly lower with degludec: rate ratio 0.60 (95% CI 0.48 to 0.76), P<0.001 [1].

Current FDA Label Scope

The current prescribing information lists Tresiba U-100 and U-200 FlexTouch pens. The U-200 formulation delivers up to 160 units per injection in a smaller volume, a practical feature for patients requiring high daily doses. The FDA label includes a boxed warning shared by all insulins regarding hypoglycemia risk. Dosing conversion from other basal insulins is unit-to-unit on a once-daily basis [2].

Tresiba Regulatory Status in the European Union

The European Medicines Agency (EMA) granted marketing authorization for insulin degludec on January 9, 2013, making the EU the first major regulatory jurisdiction to approve the drug. The Committee for Medicinal Products for Human Use (CHMP) evaluated data from the BEGIN trial program, which included nine phase 3 studies across type 1 and type 2 diabetes. The EMA authorization covered adults initially; a pediatric indication was added following the completion of the BEGIN YOUNG trial in children aged 1 to 17 years.

BEGIN Trial Program Overview

The BEGIN program randomized more than 4,000 patients across its nine studies [3]. BEGIN Basal-Bolus Type 1 (N=629) demonstrated that degludec achieved non-inferior HbA1c reduction compared with glargine while producing significantly less confirmed nocturnal hypoglycemia: rate ratio 0.75 (95% CI 0.59 to 0.96) [3]. BEGIN Once Long Type 2 (N=1,030) showed similar glycemic control with degludec versus glargine in insulin-naive type 2 patients over 52 weeks, again with fewer confirmed nocturnal hypoglycemic episodes [4].

EMA Renewal and Post-Marketing Commitments

EMA marketing authorizations undergo periodic renewal every five years initially, then move to unlimited authorization. Novo Nordisk's degludec authorization transitioned to unlimited status following its first renewal. The EMA's European Public Assessment Report (EPAR) for Tresiba is publicly accessible and documents each post-marketing safety update. The most recent EPAR revision incorporated DEVOTE cardiovascular outcomes data, reinforcing the drug's benefit-risk balance in high-risk populations [5].

Tresiba Regulatory Status in Canada

Health Canada granted marketing authorization for insulin degludec in 2013 under the brand name Tresiba, with the approval covering type 1 and type 2 diabetes in adults. The product monograph aligns closely with the EU label given that the Canadian review relied substantially on the EMA dossier and the BEGIN program data [6].

Pediatric Coverage in Canada

The Canadian product monograph was updated to include patients aged 1 year and older after Health Canada reviewed pediatric pharmacokinetic and safety data. Dosing guidance in the monograph specifies starting doses of 10 units once daily (or conversion at a 1:1 ratio from prior basal insulin) for adults, with individualized titration targeting fasting plasma glucose of 4.0 to 7.2 mmol/L [6].

Coverage and Formulary Status

Federal coverage through the Non-Insured Health Benefits (NIHB) program and provincial drug plans varies. Ontario's Ontario Drug Benefit (ODB) formulary lists Tresiba as a limited-use benefit requiring prescriber justification based on documented hypoglycemia risk or clinical need. British Columbia and Alberta have their own tiered access criteria. Patients with private insurance generally have broader access, though prior authorization requirements remain common across payers.

Tresiba Regulatory Status in the United Kingdom

Following the UK's withdrawal from the European Union, the Medicines and Healthcare products Regulatory Agency (MHRA) retained all EMA marketing authorizations that were valid on December 31, 2020. Tresiba's EU authorization was grandfathered into a UK Marketing Authorisation (MA) without requiring a separate clinical dossier submission. The MHRA continues to accept the same approved indications: type 1 and type 2 diabetes in adults and children aged 1 year and older [7].

NHS Formulary and NICE Guidance

The National Institute for Health and Care Excellence (NICE) reviewed long-acting insulin analogues in its technology appraisal TA288 and subsequent updates. NICE guidance recommends considering insulin degludec when there is a confirmed risk of recurrent symptomatic hypoglycemia or nocturnal hypoglycemia that affects quality of life, or when the patient requires a flexible injection schedule. NHS England's indicative prescribing guidance aligns with this, positioning degludec as an option after glargine U-100 in most formulary hierarchies but as a first-line basal choice when hypoglycemia burden is documented [7].

Mechanism of Action: How Does Tresiba Work?

Insulin degludec is an ultra-long-acting basal insulin analogue. After subcutaneous injection, it forms soluble multi-hexamer chains at the injection site rather than the traditional hexamers formed by other insulins. This depot slowly releases monomers into the bloodstream, producing a flat, stable pharmacokinetic and pharmacodynamic profile [8].

Molecular Structure

Degludec differs from human insulin at two points. Threonine at position B30 is deleted, and a 16-carbon fatty diacid is attached via a glutamic acid linker to lysine at B29 [8]. The fatty acid chain mediates strong albumin binding in plasma, which further prolongs the molecule's half-life to more than 25 hours and extends its glucose-lowering effect beyond 42 hours. No other approved basal insulin has a published duration of action this long under steady-state conditions.

Pharmacokinetic Profile at Steady State

At steady state, degludec shows a coefficient of variation (CV) for day-to-day pharmacodynamic variability of approximately 20%, roughly half the 43% CV reported for glargine U-100 in the same crossover clamp study [9]. The FDA pharmacology review cited this reduced variability as a potential contributor to the lower hypoglycemia rates observed in clinical trials. The flat profile also means that the timing of injection can shift by up to 8 to 40 hours between consecutive doses in adults without clinically meaningful impact on glycemic control, as assessed in a dedicated crossover study of 88 patients [10].

Glucose-Lowering Duration Compared With Other Basal Insulins

The table below provides a direct comparison of key pharmacokinetic parameters for approved basal insulins, based on euglycemic clamp studies cited in published literature.

| Insulin | Half-life | Duration of Action | Day-to-Day PD Variability (CV%) | |---|---|---|---| | Degludec (Tresiba) | >25 h | >42 h | ~20% | | Glargine U-300 (Toujeo) | ~19 h | ~36 h | ~22% | | Glargine U-100 (Lantus) | ~12 h | ~24 h | ~43% | | Detemir (Levemir) | ~5.7 to 7.4 h | ~18 to 24 h | ~27% |

Sources: manufacturer prescribing information and peer-reviewed clamp studies [8][9][11].

DEVOTE Trial: The Evidence That Changed the Label

DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) was the key cardiovascular outcomes trial that satisfied the FDA's 2013 requirement and provided post-marketing evidence for the EU and Canada [1].

Trial Design and Patient Population

DEVOTE was a randomized, double-blind, treat-to-target trial. Patients required either established cardiovascular disease or chronic kidney disease stage 3 or higher, or were aged 60 years or older with at least two cardiovascular risk factors. Mean baseline HbA1c was 8.4%, mean age was 65 years, and 85% of participants had prior cardiovascular disease [1].

Primary and Secondary Outcomes

The primary endpoint (first MACE: cardiovascular death, non-fatal MI, or non-fatal stroke) occurred in 8.5% of degludec patients versus 9.3% of glargine patients: HR 0.91 (95% CI 0.78 to 1.06), confirming non-inferiority [1]. The pre-specified secondary endpoint of severe hypoglycemia showed a 40% relative risk reduction with degludec: rate ratio 0.60 (95% CI 0.48 to 0.76), P<0.001 [1]. Confirmed nocturnal severe hypoglycemia was 53% lower with degludec (rate ratio 0.47, 95% CI 0.31 to 0.73) [1].

The DEVOTE-2 sub-study, published separately in Diabetologia, found that each severe hypoglycemic episode was independently associated with a 3-fold higher risk of cardiovascular death in the subsequent 15 days, providing mechanistic context for why reducing hypoglycemia matters beyond patient comfort [12].

Glycemic Equivalence

End-of-trial HbA1c was 7.5% in both groups, confirming treat-to-target equivalence despite the difference in hypoglycemia rates [1]. This dissociation between equal glycemic control and unequal hypoglycemia risk is a clinically important finding. It means that a clinician can expect similar HbA1c outcomes when switching from glargine U-100 to degludec while simultaneously reducing nocturnal hypoglycemia burden.

Approved Indications, Doses, and Formulations

Tresiba is approved for glycemic control in adults and children aged 1 year and older with type 1 or type 2 diabetes mellitus. It is not approved for diabetic ketoacidosis. The two available concentrations serve different clinical needs.

U-100 vs. U-200 FlexTouch

The U-100 pen delivers 1 to 80 units per injection in 1-unit increments. The U-200 pen delivers 2 to 160 units per injection in 2-unit increments, with the same number of pen "clicks" as the U-100 version but twice the insulin per unit of volume. This design helps patients requiring more than 80 units per day avoid multiple injections or large injection volumes. The U-200 formulation is not bioequivalent on a volume basis: prescribers must confirm the patient understands they are measuring in units, not milliliters [2].

Dosing Guidance

For insulin-naive type 2 diabetes patients, the label recommends starting at 10 units once daily, then titrating by 2 units every 3 to 4 days to reach fasting self-monitored glucose targets. For patients converting from another basal insulin, the conversion is 1:1 (unit for unit) on a once-daily schedule [2]. The American Diabetes Association (ADA) 2024 Standards of Care recommend evaluating basal insulin options based on hypoglycemia risk, and note that degludec and glargine U-300 carry lower nocturnal hypoglycemia risk than glargine U-100 or detemir [13].

Flexible Dosing Window

A dedicated phase 3b trial (N=722) showed that degludec injected at a flexible time each day (varying by 8 to 40 hours between doses) maintained non-inferior HbA1c to fixed once-daily dosing after 26 weeks: estimated treatment difference 0.04% (95% CI -0.10 to 0.18) [10]. This makes degludec the only approved basal insulin with a label explicitly supporting flexible timing, a clinically relevant advantage for shift workers or patients with irregular schedules.

Safety Profile and Hypoglycemia Risk Comparison

Hypoglycemia is the primary safety concern with any insulin. DEVOTE provides the most rigorous head-to-head comparison with glargine U-100 in a high-risk population [1]. The reduction in severe hypoglycemia with degludec was consistent across pre-specified subgroups including patients with prior severe hypoglycemia (rate ratio 0.56, 95% CI 0.40 to 0.77) [1].

Injection Site and Allergic Reactions

The prescribing information documents lipodystrophy and cutaneous amyloidosis as rare injection-site reactions, both common to the insulin class [2]. Systemic allergic reactions, including anaphylaxis, have been reported rarely. The label advises rotating injection sites within the same region and monitoring for skin thickening or pitting.

Drug Interactions Relevant to Prescribers

Thiazolidinediones (pioglitazone, rosiglitazone) may cause fluid retention and heart failure when combined with insulin, including degludec. Antidiabetic agents that lower blood glucose can increase hypoglycemia risk when added to degludec. Corticosteroids, atypical antipsychotics, and protease inhibitors may increase insulin requirements [2].

Biosimilar and Generic Field

As of 2025, no FDA-approved biosimilar for insulin degludec exists in the United States. Novo Nordisk's composition-of-matter patents covering the degludec molecule and its multi-hexamer depot mechanism extend patent exclusivity in the US through the late 2020s, though exact expiry dates depend on ongoing patent litigation. The EU granted biosimilar pathways under EMA guidelines for insulin biosimilars, but no degludec biosimilar has received EMA approval to date. Canada and the UK face similar timelines given the same patent estate.

The absence of biosimilar competition keeps Tresiba's list price in the US above USD 300 per pen package (before manufacturer coupons), a consideration the ADA 2024 Standards of Care address by noting cost as a factor in basal insulin selection [13]. Novo Nordisk's Tresiba patient assistance and copay programs reduce out-of-pocket costs for eligible commercially insured or uninsured patients, though these programs do not benefit Medicare Part D enrollees in the coverage gap.

Pediatric Use and Special Populations

Children Aged 1 to 17 Years

The BEGIN YOUNG trial (N=350) compared degludec with detemir in children and adolescents with type 1 diabetes over 52 weeks [14]. HbA1c reduction was non-inferior (estimated treatment difference 0.15%, 95% CI -0.03 to 0.32), and the rate of confirmed hypoglycemia was similar between groups. The flexible dosing option was not specifically studied in children below age 6, and the label advises supervised use in very young children due to variable food intake and activity [2].

Renal and Hepatic Impairment

No dose adjustment is required based solely on renal or hepatic function, but both conditions may reduce insulin clearance and increase hypoglycemia risk. The label advises more frequent glucose monitoring in patients with estimated GFR <30 mL/min/1.73m2 or significant hepatic dysfunction [2].

Pregnancy

Tresiba is categorized as FDA Pregnancy Category B equivalent under the current labeling framework (before Pregnancy and Lactation Labeling Rule categories were retired). Limited human data exist. The label states that insulin requirements typically decrease in the first trimester and increase in the second and third. Most endocrinologists and the Endocrine Society's 2021 clinical practice guideline on diabetes in pregnancy recommend NPH or glargine as first-line basal insulins during pregnancy given longer post-market safety records, reserving degludec for cases of documented hypoglycemia burden [15].